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ABSTRACT
Introduction: Clinical trials have shown that
liraglutide effectively lowers glycated
hemoglobin A1c (A1C) levels in adult patients
with type 2 diabetes (T2D). However, no studies
have evaluated the effectiveness of liraglutide
by body mass index (BMI) in the United States
(US) in clinical practice. This study examined
liraglutide’s clinical effectiveness to lower A1C
and body weight after 6 months in T2D patients
stratified by baseline BMI.
Methods: This was a retrospective cohort study
using the General Electric Centricity electronic
medical records database. Adult patients with
T2D (C18 years and BMIC 25 kg/m2) and A1C
[7% at baseline who started liraglutide between
January 1, 2010 and January 31, 2013 and who
did not use insulin or a glucagon-like peptide-1
analog 12 months before initiating liraglutide
(N = 3,005) were selected. Changes from
baseline, stratified by BMI, in A1C, body
weight, A1C \7% goal attainment, and
incidence of severe hypoglycemia at 6-month
follow-up were examined.
Results: After 6 months, A1C levels decreased on
average by 0.95%, 1.02%, 0.99%, and 0.84% for
BMI categories 25.0–29.9 (n = 333), 30.0–34.9
(n = 793), 35.0–39.9 (n = 821), and C40.0 kg/m2
(n = 1,058), respectively (P = 0.30). The
proportions of patients achieving A1C \7% at
6 months were 38.2%, 37.0%, 40.9%, and 41.0%
(P = 0.54). The absolute body weight decreased
by 1.5 to 4.0 kg across BMI and the rate of severe
hypoglycemia (0.2%) was low.
Conclusion: Patients with T2D experienced
statistically significant decreases in A1C and
body weight after initiating liraglutide regardless
of their BMI. Liraglutide reduced A1C equally well
across baseline BMI in clinical practice in the US.
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INTRODUCTION
In recent years, diabetes mellitus has emerged as
a global public health concern. Already the
most common metabolic disorder, the global
prevalence rates of diabetes have been
increasing [1]. As of 2012, about 9.3% of the
US population (29.1 million people of all ages)
were affected by diabetes, which was the
seventh leading cause of death in the United
States (US) [2]. The American Diabetes
Association (ADA) estimated the total costs of
diagnosed diabetes to be $245 billion in 2012,
which increased from $174 billion in 2007 [3].
Numerous complications are linked to diabetes
including heart disease, stroke, hypertension,
and kidney disease, which could potentially
increase total costs incurred [2]. About 90–95%
of all diabetes cases involve type 2 diabetes
(T2D); therefore, the clinical and economic
burdens incurred by T2D need to be
investigated [2].
Liraglutide is a once-daily glucagon-like
peptide-1 (GLP-1) receptor agonist used to
improve glycemic control in adults with T2D.
The liraglutide effect and action in diabetes
(LEAD) pivotal clinical trials and the 1860
liraglutide dipeptidyl peptidase-4 inhibitor
(LIRA-DPP-4) study have analyzed liraglutide
against various active comparators across the
treatment cascade [4–11]. These studies have
demonstrated that liraglutide improves
glycemic control with a low incidence of
hypoglycemia, and has the additional benefit
of clinically relevant weight loss.
High body mass index (BMI) is an
independent risk factor for cardiovascular
diseases and all-cause mortality for people
with T2D [12, 13]. High BMI, also involved in
the pathogenesis of T2D, can complicate the
treatment of T2D by altering lipid levels,
increasing insulin resistance, and raising blood
glucose levels [13]. Several studies have
examined changes in body weight, BMI, or
body fat over a follow-up period for patients
treated with liraglutide, given the effects of
excess body weight in T2D patients. Substantial
weight reduction [12–18] or BMI reduction [12,
17, 19] was found in several investigations.
However, to date, no study has evaluated the
relative clinical effectiveness of liraglutide to
achieve glycemic control and weight loss in
patients with T2D across baseline BMI levels in
real-world clinical practice in the US. The
objective of this study is to address this gap
and examine liraglutide’s effectiveness on
glycated hemoglobin A1C (A1C) (a minor
component of hemoglobin to which glucose is
bound), body weight, cholesterol, and blood
pressure across different BMI levels.
METHODS
Data Source
The data for this retrospective cohort study were
obtained from the General Electric (GE)
Centricity electronic medical record (EMR)
database from January 1, 2009 to January 31,
2013. The GE Centricity EMR database contains
data on more than 15 million individuals
receiving care from more than 10,000 general
practitioners. Forty-seven US states are
represented and the average length of follow-
up for individuals in the dataset is
approximately 3 years. The GE Centricity EMR
database contains detailed information that
typical medical claims databases do not, such
as patient demographic characteristics (patient
height, weight, BMI, and smoking status) and
certain laboratory values (cholesterol, A1C, and
vital signs [blood pressure]). This general
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practitioner (ambulatory) EMR database
provides complete information on all
prescribed drugs for patients receiving care
from that practice. Patient information from a
variety of sources is routinely integrated into a
common database and includes the number of
patient encounters, insurance data, medication
data that reflect not only prescription drug data,
but also over-the-counter (OTC) medications
prescribed by the physician, and historical drug
use. However, the GE database is unable to
provide specific dose information.
Compliance with Ethics Guidelines
This study was exempt from ethics approval
from an institutional review board and
informed consent since it involved assessment
of existing data and the subjects could not be
identified directly or through identifiers linked
to the subjects [45 CFR 46.101(b)].
Sample Selection
Patients were included in the study sample if
they had T2D and a prescription order for
liraglutide between January 1, 2010, and
January 31, 2013. The index date was defined
as the date of the first prescription order for
liraglutide. T2D was defined using the following
criteria: (1) at least one diagnosis for T2D
based on an International Classification of
Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) code for 250.x0 or 250.x2; (2)
one or more prescription orders for a non-
insulin antidiabetic drug; or (3) two consecutive
fasting blood glucose levels of C126 mg/dL [20].
These analyses focused on outcomes at
6 months after starting liraglutide (6-month
post-index).
Patients were excluded if they (1) were not
continuously enrolled during 12 months prior
to the index date (pre-index period) and during
6-month follow-up, (2) had one or more
prescription orders for any GLP-1 receptor
agonist during baseline, (3) had one or more
prescription orders for insulin use during
baseline, (4) were less than 18 years of age, (5)
had type 1 diabetes (ICD-9-CM codes: 250.x1 or
250.x3), polycystic ovarian syndrome (ICD-9-
CM code 256.4) without the presence of T2D
(ICD-9-CM codes 250.x0 or 250.x2), or were
pregnant or had gestational diabetes
(Supplemental Table 1) during any point in
time during the pre-index period, (6) or their
baseline A1C was B7% [21]. All patients were
required to have at least one valid A1C measure
at baseline (up to 45 days prior to the index
date to up to 7 days after) and at least one valid
A1C measure at their 6-month follow-up
date (±45 days) for analyses of outcomes
at 6 months follow-up. Due to very few
(N = 36) patients in the baseline BMI category
\25.0 kg/m2, this category was excluded from
the analysis.
Demographic and Clinical Characteristics
Demographic characteristics such as age,
gender, race, geographic region (Midwest,
Northeast, South, and West), and health plan
type (Commercial, Medicare, Medicaid, Self-
pay/Other, and Unknown) were captured at
baseline. Baseline clinical characteristics
included BMI and common diabetes-related
complications identified using ICD-9-CM
codes [22]. Clinical measures like A1C, weight,
blood pressure (systolic blood pressure [SBP];
diastolic blood pressure [DBP]), lipid values
(total cholesterol; high-density lipoprotein
cholesterol [HDL]), and occurrence of severe
hypoglycemia were reported at both baseline
and follow-up. Severe hypoglycemia was
defined according to type of service and ICD-
9-CM codes (Supplemental Table 2) [23] and/or
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a recorded glucose level of less than or equal to
40 mg/dL [24].
Patients may have had multiple
measurements of the clinical outcomes during
the baseline and follow-up periods. The baseline
value was defined as the value closest to the index
date (within 45 days prior to the index date to up
to 7 days after). Values for outcomes at 6-month
follow-up were defined as the measurements
that were obtained on the day closest to
180-day post-index within a ±45-day window.
All characteristics were stratified by baseline BMI
categories, which were defined as 25.0–29.9,
30.0–34.9, 35.0–39.9, and C40.0 kg/m2.
Clinical Outcomes
The authors assessed the following clinical
outcomes at 6-month follow-up: absolute
changes (follow-up minus baseline) in A1C,
weight, blood pressure, and lipids; relative
changes (absolute change divided by baseline)
in body weight; and the proportion of patients
treated with liraglutide reaching A1C targets.
The American Association of Clinical
Endocrinologists (AACE) target of A1C B6.5%
and the American Diabetes Association (ADA)
target of A1C \7% were used. Finally, the
authors examined the occurrence of severe
hypoglycemia at 6-month follow-up.
Analyses
Means and standard deviations (SD) were
reported for continuous measures and
percentages were reported for categorical
measures. Statistical significance between
baseline and follow-up values were assessed
using the paired t-test for continuous measures
and McNemar’s test for categorical measures.
Analysis of variance (ANOVA), for continuous
variables, and the Chi-square test, for
categorical variables, were used to assess the
statistical significance across the BMI categories.
Differences with a P value of less than 0.05 were
considered statistically significant. Analyses
were performed using SAS software version 9.2
(SAS Institute, Cary, North Carolina, USA).
RESULTS
A total of 3,005 patients with T2D sub-
optimally controlled at baseline (A1C [7%)
initiating liraglutide between January 1, 2010
and January 31, 2013 were identified (Fig. 1).
Table 1 shows the demographics and clinical
characteristics of the sample stratified by
baseline BMI. The mean age (SD) of the study
sample was 54.7 (10.9) years and ranged from
52.1 (10.7) to 57.8 (11.1) years across the BMI
categories (P\0.01). More than one-third of
patients in all BMI categories were in the
50–59 year age group. About 53% of the
sample was female and this proportion, too,
varied by BMI category (46.5–59.3%, P\0.01).
There were no statistically significant
differences across BMI category by race/
ethnicity, region, plan type, smoking status, or
the presence of comorbid conditions.
The mean baseline BMI (SD) of the study
sample was 38.3 (7.7) kg/m2 with group means
of 28.1 (1.3), 32.6 (1.4), 37.3 (1.4), and 46.6 (6.1)
kg/m2 for BMI categories 25.0–29.9, 30.0–34.9,
35.0–39.9, and C40.0 kg/m2, respectively.
Average (SD) baseline A1C, which was 8.65%
(1.4) for the entire sample, did not vary
significantly by BMI category (P = 0.358). Total
cholesterol and HDL measures at baseline also
did not vary significantly by BMI category
(P = 0.62 and P = 0.19, respectively). However,
blood pressure did vary by BMI category, with
blood pressure increasing as baseline BMI
increased (P\0.01). The proportion of patients
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who experienced severe hypoglycemia within
the baseline period around the index date
(45 days prior to 7 days after) was low (0.1%).
Clinical Outcomes
Table 2 shows the baseline and 6-month follow-
up values for each clinical outcome for those
patients who had available data at both time
points; the fraction of the sample with data at
both baseline and 6-month follow-up ranged
from 23% for HDL to 55% for A1C. Liraglutide
patients across all BMI categories experienced a
statistically significant decrease in A1C
(P\0.01) at 6 months from baseline ranging
from -0.84% to -1.02%. Similarly, liraglutide
patients across all BMI categories experienced
statistically significant decreases from baseline
in absolute and relative body weight, total
cholesterol, and SBP (all P\0.05) at 6 months.
The results were mixed for HDL and DBP—
significant changes from baseline to 6 months
were observed in only some BMI categories. The
proportions of patients achieving the ADA
target of A1C \7% were 38.2%, 37.0%, 40.9%,
and 41.0% for BMI categories 25.0–29.9,
30.0–34.9, 35.0–39.9, and C40.0 kg/m2,
respectively. None of these changes were
statistically significantly different across BMI
categories, except for body weight, in which
case patients in higher BMI categories tended to
lose more absolute and relative weight. In other
words, for all clinical outcomes examined,
except for body weight, patients experienced
similar decreases in A1C, total cholesterol, and
SBP regardless of their baseline BMI. These
results are displayed graphically in Figs. 2, 3, 4,
and 5. The proportion of patients with severe
hypoglycemia at 6-month follow-up was low
(0.0%, 0.7%, 0.0%, 0.2% for BMI categories
25.0–29.9, 30.0–34.9, 35.0–39.9, and C40.0 kg/m2,
respectively).
Exclude patients with prescription order of GLP-1 receptor agonist and insulin use during the pre-index period
N=23,963 
Exclude patients with type 1 diabetes, pregnancy or gestational diabetes, or polycystic ovary syndrome
N=9,191
≥ 1 A1C measure during the baseline
N= 4,949
Baseline BMI ≥25 kg/m
2
N=3,005
(Deleted  missing baseline BMI, N=259 or BMI < 25 kg/m,2 N=36)  
Patients with prescription order for Liraglutide between 1/1/2010 and 31/1/2013
N=42, 236
Adults (≥18 years ) with continuous enrollment during the 12-months pre-index period and 6-months follow-up
N=9,687
A1C >7 % measure at baseline
N= 3,300
Fig. 1 Sample selection. A1C Glycated hemoglobin A1c, BMI body mass index, GLP-1 glucagon-like peptide 1
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Age, years 54.7 (10.9) 57.8 (11.1) 56.5 (10.7) 55.0 (10.7) 52.1 (10.7) \0.01
Age, %
18–39 years 8.9 6.0 5.4 7.8 13.2 \0.01
40– 49 years 21.8 16.2 19.7 21.6 25.3
50–59 years 36.4 35.1 36.6 35.8 37.1
60–69 years 24.1 28.2 26.6 25.9 19.6
70–79 years 7.8 11.4 10.3 8.0 4.4
80? years 1.1 3.0 1.4 0.9 0.4
Gender, %
Female 52.6 50.2 46.5 50.9 59.3 \0.01
Male 47.4 49.8 53.5 49.1 40.7
Race/ethnicity, %
White 63.9 61.6 61.3 64.3 66.4 0.10
African
American
7.7 8.1 7.9 7.8 7.4
Hispanic 1.8 2.4 1.9 1.1 2.1
Other 3 4.5 3.8 3.4 1.6
Unknown 23.6 23.4 25.1 23.4 22.6
Region, %
Midwest 20.6 21.6 20.1 18.2 22.5 0.13
Northeast 19.2 18.6 17.8 19.0 20.7
South 48.3 47.5 49.4 52.1 44.7
West 11.9 12.3 12.7 10.7 12.1
Plan type, %
Commercial 33.2 29.1 33.3 35.0 33.1 0.27
Medicare 15.6 17.7 17.2 14.7 14.6
Medicaid 0.6 0.6 0.4 0.4 0.9
Self-pay/other 1.5 2.7 1.5 0.9 1.6
Unknown 49.1 49.9 47.7 49.1 49.9
Smoking status, %
Never smoked 25.0 31.8 23.0 25.2 24.2 0.13














Former smoker 30.6 26.4 32.0 30.6 30.9
Current smoker 7.5 8.1 7.9 8.0 6.6
Other/
unknown
36.9 33.6 37.1 36.2 38.3
Complications, %
Retinopathy 0.3 0.9 0.5 0.2 0.0 0.04
Nephropathy 1.1 0.9 1.6 0.7 1.1 0.37
Neuropathy 1.9 0.9 2.0 2.3 1.9 0.47
Cerebrovascular 0.2 0.3 0.3 0.2 0.0 0.43
Cardiovascular 1.1 1.8 0.8 1.6 0.8 0.15
PVD 0.1 0.0 0.0 0.2 0.1 0.42
Diabetes medications, %
Sulfonylureas 52.9 56.2 52.7 53.0 52.0 0.58
Metformin 79.8 82.3 80.3 78.7 79.4 0.54
Other OADsa 32.5 33.3 32.9 34.1 30.7 0.45
Clinical characteristics
BMI, kg/m2 38.3 (7.7) 28.1 (1.3) 32.6 (1.4) 37.3 (1.4) 46.6 (6.1) \0.01
Weight, kg 110.4 (24.5) 82.4 (10.8) 95.2 (11.9) 108.0 (13.8) 132.6 (22.3) \0.01




176.1 (43.0) 179.0 (46.1) 175.5 (44.7) 177.0 (45.0) 175.0 (38.8) 0.62
HDL 41.9 (11.4) 43.1(12.0) 42.2(11.5) 41.2(10.8) 41.7 (11.4) 0.19
Blood pressure, mmHg
SBP 129.8 (15.3) 126.4 (14.3) 128.7 (16.0) 130.3(15.0) 131.2 (15.1) \0.01
DBP 78.1 (9.6) 76.1 (9.3) 77.2 (9.7) 78.7 (9.4) 79.0 (9.8) \0.01
For appropriate variables, results presented as mean (SD)
BMI body mass index, PVD peripheral vascular disease, OADs oral antidiabetic medications, HDL high-density lipoprotein
cholesterol, SBP systolic blood pressure, DBP diastolic blood pressure
* P values were determined using analysis of variance (ANOVA), for continuous variables, and the Chi-square test, for
categorical variables, to assess statistical signiﬁcance across BMI categories
a Other OADs include alpha-glucosidase inhibitors, dipeptidyl peptidase inhibitors, thiazolidinediones and meglitinides
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DISCUSSION
This study found that liraglutide lowered A1C as
well as other key T2D-related complications
equally well across baseline BMI categories
6-month post-initiation. This study, to the
authors’ knowledge, is the first to evaluate
liraglutide’s real-world effectiveness for
different levels of BMI in clinical practice in
the US. The results of this study could provide
valuable insights to clinicians when prescribing
liraglutide to patients with T2D across different
BMI groups. The findings may also be useful to
patients and formulary decision makers when
choosing between available T2D medications.
The overall results from this study are
consistent with those of the pivotal LEAD
trials. Pooled analyses of seven Phase III
liraglutide trials found that A1C dropped by
1.05–1.15% from baseline, for 1.2 and 1.8 mg
dosages, respectively [25]. Although these
reductions were marginally larger than the
overall A1C reduction of 0.94% (AIC reduction
ranged from 0.84% and 1.02% depending on
BMI categories) found in this current study, the
results are comparable given the differences
between the tightly controlled setting of a
clinical trial and real-world clinical practice.
This same meta-analysis of clinical trials
reported that the absolute reduction in body
weight from baseline stratified by liraglutide
dose ranged from 1.69 kg (1.2 mg) to 2.27 kg
(1.8 mg) [25]. Similarly, this study reported an
overall absolute body weight reduction of
2.9 kg, ranging from 1.5 kg to 4.0 kg across
BMI groups.
The results of this study, by baseline BMI, are
consistent with two recently published studies.
No differences were found in A1C reductions
across six BMI categories before and after
adjustment for baseline factors, such as
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of British Clinical Diabetologists (ABCD)
nationwide data from the UK [26]. In addition,
in a prospective follow-up study, Fadini et al.
[15] found that liraglutide was equally effective
in reducing A1C across baseline BMI tertiles
measured at 4-month intervals, i.e., the A1C
reductions across the BMI tertiles were not
statistically significantly different from each
other (P = 0.94).
Although the authors did not find evidence
that A1C reductions were related to baseline
BMI, the study did find that absolute and
relative reductions in body weight were
dependent on baseline BMI, which is
consistent with the findings of Fadini et al.
[15] of a statistically significant association
between reductions in body weight (kg) at
4-month intervals and baseline BMI tertiles
(P\0.01), and with the findings of the UK
study conducted by Ryder et al. [26] reporting
an association between absolute weight
Fig. 2 Absolute change in A1C from baseline to 6-month
follow-up: (%). Statistical signiﬁcance across body mass
index (BMI) categories was determined through analysis of
variance (ANOVA)
Fig. 3 Changes in body weight from baseline to 6-month
follow-up. Statistical signiﬁcance across body mass index
(BMI) categories was determined through analysis of
variance (ANOVA). Upper panel absolute change in body
weight (kg), lower panel relative change in body weight (%)
Fig. 4 Changes in lipids from baseline to 6-month
follow-up. Statistical signiﬁcance across body mass index
(BMI) categories was determined through analysis of
variance (ANOVA). Upper panel absolute change in total
cholesterol (mg/dL), lower panel absolute change in
high-density lipoprotein cholesterol (mg/dL)
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reductions and greater baseline BMI resulting
from liraglutide treatment. The results of this
study for relative weight loss are also consistent
with the meta-analysis of the LEAD pivotal trials
conducted by Niswender et al. [13], namely,
those patients with higher baseline BMI lost
more relative body weight than patients with
lower baseline BMI.
Other outcomes evaluated in this study
included severe hypoglycemia, lipids, and
blood pressure. The low rate of severe
hypoglycemia that the authors found is
consistent with liraglutide’s glucose-dependent
mechanism of action and the results from the
Bode et al. [27] meta-analysis. The authors’
findings, that changes in total cholesterol and
HDL were independent of baseline BMI, are also,
if not indirectly, consistent with the findings
that total and HDL cholesterol were not related
to changes in body weight reported by Fadini
et al. [15]. The overall reductions in SBP and
DBP, respectively, were also consistent with
those reported by Bode et al. [27] of 2.87 and
1.40 mmHg (liraglutide 1.2 mg) and reductions
of 2.99 and 1.47 mmHg (liraglutide 1.8 mg).
Study Limitations
There were several limitations of this study.
First, although the authors identified over 3,000
eligible patients with baseline data, relevant
laboratory and clinical measures at 6-month
follow-up were unavailable for many of them,
as expected in a real-world study setting. The
impact of this limitation is unclear but the
authors do note that the average baseline
laboratory and clinical values for the subset of
patients with follow-up data were similar to
those of the baseline values for the entire
sample. Second, it is not possible to determine
if patients actually filled or refilled their
prescriptions using the GE Centricity EMR
database, so the authors could not examine
adherence to therapy as an outcome nor were
they able to adjust for adherence. Therefore,
this study used an intent-to-treat approach.
Third, because dose information is often
missing from drug records in the GE Centricity
EMR database, the authors could not stratify the
analyses by liraglutide dose. Fourth, the
analyses did not adjust for potential
confounding by measured (e.g., age, gender,
race) and unmeasured factors (e.g., diet,
exercise). Fifth, a post hoc power calculation
showed that the statistical power ranged from
40% to 50% for all clinical outcomes except
body weight, for which the power was about
90%. The low statistical power may affect the
ability to detect changes in clinical outcomes
Fig. 5 Changes in blood pressure from baseline to
6-month follow-up. Statistical signiﬁcance across body
mass index (BMI) categories was determined through
analysis of variance (ANOVA). Upper panel absolute
change in systolic blood pressure (mmHg), lower panel
absolute change in diastolic blood pressure (mmHg)
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across BMI levels. However, as for other
retrospective database studies, the authors had
no control over the sample size after enforcing
inclusion/exclusion criteria. Lastly, the authors
may have misclassified baseline and 6-month
follow-up measurements because the start and
end dates of liraglutide that were recorded by
physicians may have differed from actual start
and end dates. However, it is unlikely that the
possible discrepancy between actual and
recorded dates would vary in any systematic way.
CONCLUSION
The authors found that liraglutide was equally
effective in reducing A1C across baseline BMI
categories suggesting that liraglutide may be
effectively used for adult patients with T2D
regardless of their BMI level. This study provides
valuable insights for providers and formulary
decision makers as it represents the first real-
world evaluation of liraglutide’s effectiveness to
lower A1C, body weight, cholesterol, and blood
pressure across BMI groups in clinical practice in
the US.
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